Novavax
Novavax (NASDAQ: NVAX) is a biotechnology company that develops protein nanoparticle vaccines and licenses its proprietary Matrix-M adjuvant to major pharmaceutical partners (Sanofi, Pfizer, Takeda, Serum Institute) across infectious disease and oncology applications, with marketed products including Nuvaxovid and R21/Matrix-M malaria vaccine.
- Company typePublic
- Founded1987
- HeadquartersGaithersburg, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Novavax does
Novavax is a publicly traded biotechnology company (NASDAQ: NVAX) founded in 1987 and headquartered in Gaithersburg, Maryland, that develops vaccines built on two proprietary technology platforms: recombinant protein-based nanoparticles that mimic target pathogen antigens, and the Matrix-M saponin-based adjuvant, derived from soapbark tree compounds, which enhances the magnitude and duration of immune response. Its marketed portfolio consists of Nuvaxovid (a COVID-19 vaccine whose U.S. and EU commercial rights have been transferred to Sanofi) and the R21/Matrix-M malaria vaccine distributed by the Serum Institute of India, which has achieved over 80% market share with 30 million doses sold since mid-2024. The company also operates a Sweden-based R&D unit in Uppsala (Novavax Sweden) housing the Matrix-M inventor Karin Lövgren Bengtsson, and has a U.S. headquarters plus a former Czech manufacturing facility sold to Novo Nordisk in 2025 for $200 million.
Following the COVID-19 pandemic, Novavax executed a strategic pivot from a vertically integrated vaccine manufacturer to a partnership-driven adjuvant and technology licensing platform. Revenue is generated through four streams: direct Nuvaxovid product sales under legacy APA and commercial agreements (declining as Sanofi assumes commercial responsibility); supply sales of finished product and Matrix-M adjuvant to license partners (Sanofi, Takeda, Serum Institute); licensing, royalties, and milestone payments (Sanofi $1.2B deal, Pfizer $530M Matrix-M license announced January 2026 with $30M upfront and up to $500M in milestones); and R&D reimbursements under the Sanofi co-exclusive licensing agreement (expected $70-80M in 2026). Customer segments include pharmaceutical partners licensing Matrix-M for vaccine development across infectious diseases and oncology, adults 65+ and high-risk populations for COVID-19 vaccination, and global health/malaria programs through the R21/Matrix-M partnership. The company employs 501-1,000 people and is led by President and CEO John C. Jacobs, with Dr. Robert Walker appointed as EVP and Head of R&D in March 2026.
Novavax firmographics
Firmographics- Name
- Novavax
- Legal name
- Novavax, Inc.
- Website
- https://novavax.com
- Company type
- Public
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Novavax (NASDAQ: NVAX) is a biotechnology company that develops protein nanoparticle vaccines and licenses its proprietary Matrix-M adjuvant to major pharmaceutical partners (Sanofi, Pfizer, Takeda, Serum Institute) across infectious disease and oncology applications, with marketed products including Nuvaxovid and R21/Matrix-M malaria vaccine.
- Ownership category
- akta.pro rank
Novavax industry classification
Industry- Product category
- Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where Novavax is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Novavax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Nuvaxovid Product Sales: Direct product sales of Nuvaxovid COVID-19 vaccine where Novavax is commercial market lead. Revenue declining as responsibility transitions to Sanofi.
- Supply Sales: Sales of finished product, adjuvant, and other supplies from Novavax to its license partners including Sanofi, Takeda, and Serum Institute.
- Licensing, Royalties and Milestones: Revenue from license agreements including upfront payments, milestones, and royalties. Includes $30M Pfizer upfront, Sanofi milestones ($225M earned in 2025), and tiered royalties on partner product sales.
- R&D Reimbursements: Under Sanofi co-exclusive licensing agreement, Novavax receives reimbursement for costs related to select R&D and technology transfer activities during transition period. $70-80M expected in 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Nuvaxovid product sales under existing APA and commercial agreements |
| Unit Pricing | Multi-year contract | Supply sales to partners |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Novavax product offering
Product offeringCore offering
Novavax is a biotechnology company that develops and commercializes vaccines built on its proprietary Matrix-M saponin-based adjuvant combined with recombinant protein nanoparticle antigens. It markets Nuvaxovid (COVID-19) and R21/Matrix-M (malaria, with Serum Institute), while monetizing the Matrix-M platform primarily through licensing deals, milestone payments, and royalties with pharmaceutical partners including Sanofi, Pfizer, and Takeda.
Product overview
Novavax is a biotechnology company focused on vaccine development with a proprietary technology platform combining Matrix-M adjuvant and protein-based nanoparticles. The marketed product portfolio includes Nuvaxovid (COVID-19 vaccine, with commercial rights transferred to Sanofi) and R21/Matrix-M malaria vaccine (partnered with Serum Institute). The company generates revenue through licensing its Matrix-M technology to major pharmaceutical partners including Sanofi, Pfizer, and Takeda. The pipeline includes COVID-19-influenza combination vaccines, standalone influenza vaccine, C. difficile vaccine, shingles vaccine, and RSV vaccine candidates, all leveraging the Matrix-M adjuvant platform.
Differentiator
Problem solved
Functional benefit
Brands
- Matrix-M: Proprietary saponin-based adjuvant technology that enhances immune response in vaccines
- Nuvaxovid
- R21/Matrix-M
Products and services
- Matrix-M Adjuvant Technology Proprietary saponin-based adjuvant technology that enhances the magnitude and duration of immune response in vaccines. Licensed to Sanofi, Pfizer, Takeda, and other pharmaceutical partners for use across infectious disease and oncology vaccine development. Novavax manufactures and supplies the adjuvant while partners handle product development and commercialization.
- Nuvaxovid (NVX-CoV2373) COVID-19 Vaccine Protein-based COVID-19 vaccine combining recombinant nanoparticle antigen (NVX-CoV2373) with Matrix-M adjuvant. Commercialized by Sanofi in the U.S. and EU, by Takeda in Japan, and supplied to government vaccination programs including Singapore's National Vaccination Programme.
- R21/Matrix-M Malaria Vaccine Malaria vaccine leveraging Matrix-M adjuvant technology, developed and commercialized with Serum Institute of India. Indicated for prevention of P. falciparum malaria in children in endemic regions including Africa; supplied through COVAX and global health channels.
- COVID-19-Influenza Combination Vaccine Combined COVID-19 and influenza vaccine candidate in Phase 3 development, leveraging Matrix-M adjuvant with recombinant nanoparticle antigens. Sanofi is advancing toward regulatory filing with potential 2027-2028 approval.
- Stand-alone Influenza Vaccine Recombinant quadrivalent influenza vaccine candidate in Phase 3 development using Matrix-M adjuvant technology.
- C. difficile Vaccine Candidate Clostridioides difficile colitis vaccine candidate in preclinical development, leveraging Novavax's recombinant nanoparticle and Matrix-M adjuvant platform. Identified as a potential next asset to enter clinical trials.
- Varicella-Zoster Virus (Shingles) Vaccine Candidate Preclinical vaccine candidate targeting shingles (Varicella-Zoster Virus) using Novavax's recombinant nanoparticle and Matrix-M adjuvant platform.
- RSV Vaccine Candidates Respiratory syncytial virus (RSV) vaccine candidates in early-stage development leveraging Novavax's Matrix-M adjuvant technology.
- H5N1 Vaccine Candidate Preclinical H5N1 avian influenza vaccine candidate that has demonstrated immunogenicity against currently circulating H5N1 variants in preclinical studies using Matrix-M adjuvant technology.
Quantifiable outcome
- R21/Matrix-M malaria vaccine achieved 80%+ market share with 30 million doses sold since mid-2024 launch
- +2 more outcomes
Companies that use Novavax
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Novavax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Novavax partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship and secondary.
- PfizercoreNon-exclusive license agreement granting Pfizer rights to use Matrix-M adjuvant technology for up to two infectious disease vaccine programs. Novavax receives $30 million upfront with potential for up to $500 million in development and sales milestones, plus high mid-single digit percentage royalties. Pfizer controls development and commercialization while Novavax supplies Matrix-M.
- Sanofiflagship$1.2 billion licensing deal for commercialization of Nuvaxovid and Matrix-M technology. Sanofi took over US and EU marketing authorization in late 2024. Novavax earned $225 million in milestones in 2025. Sanofi developing COVID-flu combination vaccine with potential 2027-2028 approval. Novavax eligible for up to $350 million in Phase 3 and launch milestones plus royalties.
- TakedacoreTakeda manufactures and commercializes Nuvaxovid in Japan. Achieved 12% market share in Japan. Takeda triggered milestone payment following regulatory approval of the COVID-19 vaccine in Japan.
- Serum Institute of IndiacoreManufacturing and distribution partner for R21/Matrix-M malaria vaccine. 30 million doses sold since mid-2024 launch, achieving over 80% market share. Major supplier for COVAX and global malaria prevention efforts.
- SK biosciencesecondary$85 million equity investment acquiring 6.5 million shares. Extended license agreement for COVID-19 variant vaccine rights in South Korea, Thailand, and Vietnam. Partnership shifting from pandemic-focused to endemic-focused response.
- Material Transfer Agreement PartnerssecondaryMultiple MTAs with pharmaceutical companies exploring Matrix-M utility across over 30 fields of experimentation including infectious diseases and oncology. Includes top 10 global pharma and oncology-focused companies. Goal is to convert MTAs into deeper licensing partnerships.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Novavax competitors and assessment
Company assessmentBroad incumbents
- CSL Seqirus: Global influenza vaccine leader and a competitor in the seasonal flu space where Novavax is advancing a Matrix-M-adjuvanted standalone flu vaccine through Phase 3 with Sanofi.
- Sanofi: Top-10 global pharmaceutical company and Novavax's largest commercialization partner for Nuvaxovid and Matrix-M; comparable as a major vaccine incumbent with broad infectious disease portfolio and the partnership economics dictate much of Novavax's near-term value.
- Pfizer: Top-10 global pharmaceutical company and Matrix-M licensee as of January 2026; comparable as a vaccine incumbent whose own COVID-19 franchise competes with Nuvaxovid while its licensing agreement creates upside for Novavax.
- GSK: Global vaccine leader with adjuvant expertise (AS01 system) and broad infectious disease portfolio; comparable as an incumbent developing and commercializing adjuvanted vaccines that could compete with or complement Matrix-M-partnered products.
Direct peers
- Moderna: Directly comparable COVID-19 vaccine developer that competes head-to-head with Novavax's Nuvaxovid in the US, EU, and other markets, and is now advancing a similar COVID-influenza combination vaccine strategy.
- BioNTech: Co-developer of the Pfizer-BioNTech COVID-19 vaccine and a direct competitor to Nuvaxovid in the protein-subunit vs mRNA vaccine market, with overlapping infectious disease pipeline ambitions.
- Dynavax Technologies: Adjuvant-focused vaccine company whose CpG 1018 adjuvant competes with Novavax's Matrix-M for inclusion in partner vaccines; comparable business model built around licensing an adjuvant technology platform.
- Valneva: Specialty vaccine developer focused on travel and endemic infectious diseases with a similar mid-cap, partnership-driven commercialization model targeting comparable disease areas.
- Bavarian Nordic: Mid-cap vaccine company with comparable scale and partnership-based commercialization, focused on infectious disease and oncology vaccines that could leverage adjuvanted technology.
Emerging players
- Emergent BioSolutions: Mid-cap vaccine/biodefense company with comparable scale and a focus on infectious disease vaccines, including adjuvanted candidates that overlap with Novavax's pipeline in C. difficile and other indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights6 records
Customer concentration
Novavax social profiles
Digital presenceNovavax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novavax leadership team
Management profileNumber of profiles
Profiles4 records
Novavax subsidiaries and ownership
Company hierarchySubsidiaries2 records
Novavax funding detail
Funding detailFunding overview
Funding rounds13 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novavax M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novavax
What does Novavax do?
Novavax is a biotechnology company that develops and commercializes vaccines built on its proprietary Matrix-M saponin-based adjuvant combined with recombinant protein nanoparticle antigens. It markets Nuvaxovid (COVID-19) and R21/Matrix-M (malaria, with Serum Institute), while monetizing the Matrix-M platform primarily through licensing deals, milestone payments, and royalties with pharmaceutical partners including Sanofi, Pfizer, and Takeda.
Is Novavax a public or private company?
Novavax is a public company. It is classified as public and is currently operating.
When was Novavax founded?
Novavax was founded in 1987. It employs 501 to 1,000 people.
Where is Novavax based?
Novavax is headquartered in Gaithersburg, United States, in the North America region.
How does Novavax make money?
Four revenue lines are on record. Nuvaxovid Product Sales are the primary driver. The others are supply Sales, licensing, Royalties and Milestones and R&D Reimbursements.
Who are Novavax's main competitors?
Broad incumbents on record are CSL Seqirus, Sanofi, Pfizer and GSK. Direct peers are Moderna, BioNTech, Dynavax Technologies, Valneva and Bavarian Nordic. Emergent BioSolutions is listed as an emerging player.
Does Novavax have an API?
No public API is recorded for Novavax.
What industry is Novavax in?
Novavax's product category is Vaccines. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2836.